3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Rectal Neoplasms
2
Neoplasms
2
Lymphoma
2
Insulin-Like Growth Factor I, Resistance To
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoid Tumor
2
Sarcoma, Ewing
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Jaundice
1
Immunoblastic Lymphadenopathy
1
Interventions
Cholangiopancreatography, Endoscopic Retrograde
2
ganitumab
1
Stents
1
Gemcitabine
1
Endoscopic Ultrasound-Guided Fine Needle Aspiration
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Jaundice
×
ganitumab
×
Clear all
NCT01231347
2024-07-16
GAMMA
NantCell, Inc.
Phase 3
Completed
800 enrolled
11 charts